FINV vs. CRSP
FINV (FinVolution Group) and CRSP (CRISPR Therapeutics AG) are both stocks. FINV operates in Credit Services (Financial Services), while CRSP operates in Biotechnology (Healthcare). Over the past 5 years, FINV returned -4.69%/yr vs -17.08%/yr for CRSP. At a 0.19 correlation, their price movements are largely independent.
Performance
FINV vs. CRSP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, FINV achieves a 2.28% return, which is significantly higher than CRSP's -5.03% return.
FINV
- 1D
- 1.62%
- 1M
- 6.12%
- YTD
- 2.28%
- 6M
- 1.69%
- 1Y
- -38.52%
- 3Y*
- 8.84%
- 5Y*
- -4.69%
- 10Y*
- —
CRSP
- 1D
- -0.86%
- 1M
- 2.87%
- YTD
- -5.03%
- 6M
- -12.14%
- 1Y
- 20.41%
- 3Y*
- -6.43%
- 5Y*
- -17.08%
- 10Y*
- —
FINV vs. CRSP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FINV FinVolution Group | 2.28% | -20.07% | 45.47% | 4.39% | 6.39% | 89.23% | 8.51% | -22.85% | -49.37% | -46.54% |
CRSP CRISPR Therapeutics AG | -5.03% | 33.23% | -37.12% | 54.00% | -46.36% | -50.51% | 151.39% | 113.18% | 21.68% | 38.53% |
Correlation
The correlation between FINV and CRSP is 0.29, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.29 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.25 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2017 | 0.19 |
Fundamentals
FINV:
$1.29B
CRSP:
$4.78B
FINV:
CN¥8.34
CRSP:
-$6.24
FINV:
0.68
CRSP:
1.11K
FINV:
0.54
CRSP:
2.64
FINV:
CN¥13.24B
CRSP:
$4.10M
FINV:
CN¥10.21B
CRSP:
-$171.17M
FINV:
CN¥2.61B
CRSP:
-$509.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
FINV vs. CRSP — Risk / Return Rank
FINV
CRSP
FINV vs. CRSP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for FinVolution Group (FINV) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| FINV | CRSP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.15 | ||
| Sortino ratioReturn per unit of downside risk | -2.04 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.11 | -0.24 |
| Calmar ratioReturn relative to maximum drawdown | -0.71 | 0.49 | -1.20 |
| Martin ratioReturn relative to average drawdown | -0.96 | 0.81 | -1.77 |
Loading charts...
Drawdowns
FINV vs. CRSP - Drawdown Comparison
The maximum FINV drawdown since its inception was -89.76%, which is greater than CRSP's maximum drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for FINV and CRSP.
Loading charts...
Drawdown Indicators
| FINV | CRSP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -89.76% | -85.11% | -4.65% |
Max Drawdown (1Y)Largest decline over 1 year | -56.42% | -42.25% | -14.17% |
Max Drawdown (3Y)Largest decline over 3 years | -56.42% | -64.91% | +8.49% |
Max Drawdown (5Y)Largest decline over 5 years | -70.54% | -80.68% | +10.14% |
Current DrawdownCurrent decline from peak | -49.54% | -76.29% | +26.75% |
Average DrawdownAverage peak-to-trough decline | -54.09% | -49.24% | -4.85% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 41.69% | 25.51% | +16.18% |
Volatility
FINV vs. CRSP - Volatility Comparison
FinVolution Group (FINV) and CRISPR Therapeutics AG (CRSP) have volatilities of 19.10% and 18.22%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| FINV | CRSP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 19.10% | 18.22% | +0.88% |
Volatility (6M)Calculated over the trailing 6-month period | 33.29% | 43.62% | -10.33% |
Volatility (1Y)Calculated over the trailing 1-year period | 48.91% | 62.44% | -13.53% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 49.99% | 60.65% | -10.66% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 71.75% | 64.35% | +7.40% |
Dividends
FINV vs. CRSP - Dividend Comparison
FINV's dividend yield for the trailing twelve months is around 6.08%, while CRSP has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
CRSP CRISPR Therapeutics AG | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
FINV FinVolution Group | 6.08% | 5.30% | 3.49% | 4.39% | 4.13% | 3.45% | 4.49% | 7.17% |
Financials
FINV vs. CRSP - Financials Comparison
This section allows you to compare key financial metrics between FinVolution Group and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
FINV and CRSP have a correlation of 0.29, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
FINV has higher volatility (19.10%) compared to CRSP (18.22%). In terms of maximum drawdown, FINV dropped -89.76% vs CRSP's -85.11%.
CRSP currently has the higher Sharpe Ratio (0.33 vs -0.82), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for FINV and CRSP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer